Manufacturing Pharmaceutical Reporting 
Mad in America
FEBRUARY 20, 2024
A new study published in the Journal of Affective Disorders Reports sheds light on this issue, offering insights from patients diagnosed with Major Depressive Disorder (MDD) who have experienced antidepressant treatment. Maelys Touya was an employee of Lundbeck LLC, and Lambros Chrones was an employee of Takeda Pharmaceuticals U.S.A.,
Mad in America
SEPTEMBER 7, 2024
” Although sexual dysfunction is labeled as a “side effect”, numerous patients report issues far persisting withdrawal. That rate has been increasing rapidly: “From 2006 to 2014, the number of serious ADEs reported to the FDA increased 2-fold… A previously published study… found that from 1998 to 2005, there was a 2.6-fold
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mad in America
AUGUST 3, 2024
In 2000, JAMA reported the US yearly estimated iatrogenic deaths: 12,000 caused by unnecessary surgeries; 27,000 caused by medication errors and other errors in hospitals; 80,000 hospital/healthcare facility acquired infections; and 106,000 “non-error” adverse effects of medication. had no clinically significant benefit over a placebo.”
Mad in America
OCTOBER 30, 2023
In this blog, he discusses the failures of the publicly funded long-term studies, CATIE and STAR*D, and psychiatry’s fraudulent reporting of these results. In their disclosure statements, 10 of STAR*D’s authors reported receiving money from Forest, Lundbeck’s partner in the United States.
Mad in America
OCTOBER 28, 2023
As you know, a RIAT patient-level analysis of the STAR*D summary findings, which were published in the American Journal of Psychiatry in November 2006, found that the cumulative remission rate was 35%, rather than the 67% reported in the Am J of Psychiatry article. Note: this sample includes the 2,876 reported in Trivedi et al.
Mad in America
NOVEMBER 13, 2023
335 In 2000, they co-authored a report of a depression pill trial in New England Journal of Medicine where the authors had so many ties to drug companies that there wasn’t room for them in the print journal (they took up 1067 words). In 2012, the US Centers for Disease Control reported that 25% of Americans have a mental illness.
Mad in America
OCTOBER 18, 2023
For the pharmaceutical industry, the bigger and wider those diseases, the more people who can be diagnosed, and the bigger your markets are. The marketing of medical conditions has become a key plank of pharmaceutical industry marketing. Helping widen the definitions of disease is a key part of marketing those pharmaceutical products.
Expert insights. Personalized for you.
121 
Let's personalize your content